- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00322504
Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study
January 6, 2010 updated by: University of New Mexico
To assess the efficacy of acupuncture treatment in reducing symptoms of anxiety in women recently diagnosed with cancer.
• To assess the efficacy of acupuncture treatment on improving perceived quality of life in women recently diagnosed with cancer.
Study Overview
Detailed Description
This is a feasibility study of acupuncture for anxiety reduction in women with breast cancer.
Ten patients will be recruited at the UNM Cancer Research Treatment Center via the Breast Clinic and screened for anxiety.
Treatment will consist of 10 acupuncture sessions over 5 weeks.
Measures (Hopkins Symptom Checklist, Sheehan Disability Index) will be administered and analyzed for treatment effect on scores.
Study Type
Interventional
Enrollment
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87114
- University of New Mexico
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Woman age 18 years or older excluding the need for parental/guardian permission.
- Histologic diagnosis of breast cancer.
- Having a minimum anxiety score of 1.75 on the Hopkins Symptom Checklist (HSCL) with sufficient English language proficiency for the investigators to make this determination.
- Able to give informed consent.
- Willingness to participate in the study and receive 10 acupuncture treatments in 5 weeks.
- Ability to fill out questionnaires and communicate with the research staff
Exclusion Criteria:
- Males with breast cancer
- Psychoses or a major personality disorder
- Current use of opiates,
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Brian Shelley, University of New Mexico
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Study Completion
September 1, 2006
Study Registration Dates
First Submitted
May 5, 2006
First Submitted That Met QC Criteria
May 5, 2006
First Posted (Estimate)
May 8, 2006
Study Record Updates
Last Update Posted (Estimate)
January 7, 2010
Last Update Submitted That Met QC Criteria
January 6, 2010
Last Verified
November 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INST 0520C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseCompletedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
Clinical Trials on Accupuncture
-
Kaiser PermanenteNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Jiangsu Province Hospital of Traditional Chinese...CompletedCancer | Colectomy | Heart Rate | Chinese Medicine | Accupuncture | Colectomy Left/Right/Total Under LaparotomyChina
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedDermatologic DiseaseTaiwan
-
Royan InstituteCompletedPoor Ovarian Response | AccupunctureIran, Islamic Republic of
-
University of Social Welfare and Rehabilitation...Completed
-
University of Social Welfare and Rehabilitation...CompletedPatellofemoral Pain SyndromeIran, Islamic Republic of